Idiotypes In Medicine Autoimmunity Infection And Cancer

This is the most comprehensive review of the idiotypic network available. All the current knowledge of idiotypes of the various antibodies is incorporated in this volume. The pathogenic role of idiotypes in autoimmunity and cancer is reviewed in depth. The therapeutic part focusses on harnessing anti-idiotypes for treating autoimmunological disorders, and on the employment of idiotypes for vaccines in cancer and infectious diseases, as well as explaining the manipulation of the idiotypic network in autoimmunity and cancer idiotypes and vaccines.

This book examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting. The chapters offer in-depth description for generating mouse and recombinant humanized antibodies, and a comprehensive review of how antibodies are being used in bead-based methods for measuring proteins. This field will continue to expand and provide new and innovative techniques in the laboratory and as a basis that complements targeted therapy.

Advances in Immunology presents current developments as well as comprehensive reviews in immunology. Articles in this volume address topics such as protein degradation and the generation of MHC class I-presented peptides, proteolysis and antigen presentation by MHC Class II molecules, cytokine memory of T-helper lymphocytes, Ig gene hypermutation, generalization of single immunological experiences by idiotypically mediated clonal connections, and aging of the immune system. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for future research.

Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.

The human foetus is separated from the maternal blood by the syncytiotrophoblast induced by endogeneous human retrovirus-encoded proteins. This barrier is a highly developed one, which suppors apical-basolateral transport of maternal idiotype and anti-idiotype IgG, IgG-virus complexes. The selective maternal-fetal transport of epitope- and paratope-bearing entities can influence the developping fetal immune system during pregnancy. The bidirectional maternal-fetal transfer of cells are of even more importance during pregnancy. Maternal cells with latent viruses transport viruses without impairment of fetal development. Cells with premaligant and malignant genetic transformation are also transported to the fetus. Fetal and neonatal tumours are initiated by such cells in spite of the antitumour potential of fetal organism. On the contary, the fetal cells repair maternal tissue injouries and survive in the organisms of the recipients for decades. These possess new consequences for the neonatal immunity and organ transplatation surgery.

Molecular farming has been hailed as the "third wave" of genetically-modified organisms produced through biotechnology for the bio-based economy of the future. Unlike products of the first wave, such as herbicide resistant crop plants, which were perceived to benefit only the farmers who used them and the agrochemical companies who developed them, products of molecular farming are designed specifically for the benefit of the consumer. Such products could be purified from food or non-food organisms for a range of applications in industry, as well as animal and human health. Alternatively, the products of this technology could be consumed more directly in some edible format, such as milk, eggs, fruits or vegetables. There is a rapidly-growing interest Qn the part of the public as well as in the medical community in the role food plays in health, especially in the immunophysiological impact of food over and above the role of basic nutrition.

The fractionation of human blood plasma can be considered to be a mature industry, with the basic technology, alcohol fractionation, dating back at least to the 1940s. Many of the products described in the current work have been approved biologics since the 1950s. The information gathered from the development of plasma proteins has proved vital to

Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index. Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic.